Osteoarthritis Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics S.A, Regeneron Pharmaceuticals, Techfi

Osteoarthritis Pipeline constitutes 100+ key companies continuously working towards developing 110+ Osteoarthritis treatment therapies, analyzes DelveInsight.

Osteoarthritis Overview:

Osteoarthritis (OA) is the most prevalent form of arthritis, often referred to as degenerative joint disease or "wear and tear" arthritis. It primarily affects the hands, hips, and knees, developing gradually as the cartilage within joints deteriorates and the underlying bone undergoes structural changes. These changes typically progress over time, leading to pain, stiffness, and swelling. In more severe cases, OA can result in reduced mobility and disability, making everyday tasks and work more challenging.

Common symptoms include joint pain that worsens with movement and improves with rest, stiffness that lasts for less than 30 minutes after periods of inactivity, and a sensation of joint instability. Additionally, affected joints may produce a grinding or creaking sound during movement, and swelling can occur, particularly after extended use.

Request for a detailed insights report on Osteoarthritis pipeline insights @ https://www.delveinsight.com/report-store/osteoarthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Osteoarthritis Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Osteoarthritis Therapeutics Market.

Key Takeaways from the Osteoarthritis Pipeline Report

DelveInsight's Osteoarthritis pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Osteoarthritis treatment.
In December 2024, Bioventus entered into a nationwide contract with Aetna Medicare Advantage plans, granting over 3 million members access to DUROLANE for knee osteoarthritis pain treatment, effective January 1, 2024.
Levicept announced in December 2024 that it had completed recruitment for its Phase II clinical trial of LEVI-04, an innovative neurotrophin-modulating biological agent, with top-line results expected in the late first half of 2024.
BioSolution plans to seek conditional product approval for CARTILIFE from the US FDA in 2024. The company is currently conducting Phase II clinical trials in the US, with the last patient set to receive treatment. Final results could be available by the end of 2024.
Key Osteoarthritis companies such as Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics S.A, Regeneron Pharmaceuticals, Techfields Pharma, Ampio Pharmaceuticals, Asahi Kasei Pharma, Taiwan Bio Therapeutics, OliPass Corporation, Bioventus, Medipost, LG Chem, ICM Biotech, Cells for Cells SA, GWOXI Stem Cell Applied Technology, UnicoCell Biomed, Magellan Biologicals, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Orient Europharma, ZYUS Life Sciences, Lubris Biopharma, Saol Therapeutics, Ageless Biotech, Synartro AB, Plakous Therapeutics, Ribomic, Meluha Therapeutics, and others are evaluating new drugs for Osteoarthritis to improve the treatment landscape.
Promising Osteoarthritis pipeline therapies in various stages of development include Lorecivivint, EP-104IAR, DFV890, 4P004, GNSC 001, and others.

Osteoarthritis Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Osteoarthritis Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Osteoarthritis treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Osteoarthritis market.

Download our free sample page report on Osteoarthritis pipeline insights @ https://www.delveinsight.com/sample-request/osteoarthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Osteoarthritis Emerging Drugs

Lorecivivint: Biosplice Therapeutics
EP-104IAR: Eupraxia Pharmaceuticals
DFV890: Novartis
4P004: 4P-Pharma
GNSC 001: Genascence

Osteoarthritis Companies

Approximately 100+ leading companies are actively developing therapies for osteoarthritis. Among them, Biosplice Therapeutics has its osteoarthritis drug candidates in the most advanced stage, specifically Phase III clinical trials.

DelveInsight's report covers around 80+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Osteoarthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Osteoarthritis Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Osteoarthritis Therapies and Key Companies: Osteoarthritis Clinical Trials and advancements @ https://www.delveinsight.com/report-store/osteoarthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Osteoarthritis Pipeline Therapeutic Assessment
• Osteoarthritis Assessment by Product Type
• Osteoarthritis By Stage
• Osteoarthritis Assessment by Route of Administration
• Osteoarthritis Assessment by Molecule Type

Download Osteoarthritis Sample report to know in detail about the Osteoarthritis treatment market @ Osteoarthritis Therapeutic Assessment @ https://www.delveinsight.com/sample-request/osteoarthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Osteoarthritis Current Treatment Patterns
4. Osteoarthritis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Osteoarthritis Late-Stage Products (Phase-III)
7. Osteoarthritis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Osteoarthritis Discontinued Products
13. Osteoarthritis Product Profiles
14. Osteoarthritis Key Companies
15. Osteoarthritis Key Products
16. Dormant and Discontinued Products
17. Osteoarthritis Unmet Needs
18. Osteoarthritis Future Perspectives
19. Osteoarthritis Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Osteoarthritis Pipeline Reports Offerings: https://www.delveinsight.com/report-store/osteoarthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.